PREDICTING HUMAN TUMOR RESPONSE BY 31P MRS

描述：这份申请来自于fccc。31-磷(31-P) 人的核磁共振波谱(MRS)共振 体内癌症表现出不同于 正常组织的那些。这些高程包括PME、PDE和 细胞pH值和聚合酶链式反应的降低。已发表的研究表明，MRS- 衍生pH和磁共振T2弛豫时间预测Soft的反应 组织肉瘤对辐射和高温的影响以及PME的变化 预测几种不同人类癌症对化疗和化疗的反应 辐射。申请人提议进行一项前瞻性试验，以检验 体内~(31)P-MRS可预测敏感性或耐药性的假设 治疗住院的癌症患者，特别适合 确定MRS在癌症治疗中的临床应用 特殊的非霍奇金淋巴瘤和局部进展型原发乳房 癌症。 这将通过将应答率和无病存活率联系起来来实现。 对基线光谱中的代谢特征和对 光谱出现在治疗开始后的早期。这 应用程序是8个交互式R01应用程序中的核心应用程序， 合作研究1500多名非霍奇金患者的机构 淋巴瘤、局部晚期乳腺癌、肉瘤和 头部和颈部。将注意患者的选择、方案 管理、技术质量控制和统计分析。这个 使用的最先进的技术将在8个国家统一 机构和将包括：(1)使用双调谐 用于各种肿瘤解剖的质子/磷表面线圈 地点。(2)磷光谱的质子去耦合区分 PME和PDE中磷脂代谢产物的单独成分 地区。(3)图像引导的三维化学位移成像 准确定位肿瘤的~(13)P核磁共振波谱，以及(4)摩尔 肿瘤中代谢物浓度的定量测定。这 应用程序还建议建立合作MRS的标准 在其他疾病和临床环境中的试验，并寻求铺平 临床试验的方法，在临床试验中，MRS可用于干预 癌症患者个体化治疗方案的选择。

DESCRIPTION: This application is from the FCCC. The 31-phosphorus (31-P) nuclear magnetic resonance (NMR) spectroscopy (MRS) resonance of human cancers in vivo reveals metabolic characteristics which differ from those of normal tissues. These include elevations in PME, PDE, and of cellular pH, and dimininution of PCr. Published studies show that MRS- derived pH and MRI-derived T2 relaxation time predict response of soft tissue sarcomas to radiation and hyperthermia, and that changes in PME's predict response of several different human cancers to chemotherapy and radiation. The applicant proposes a prospective trial to test the hypotheses that in vivo 31-P MRS can predict sensitivity or resistance to treatment inpatients with types of cancers especially well suited to determine the clinical utility of MRS in cancer management, in particular non-Hodgkin's lymphomas and locally-advanced primary breast cancers. This will be done by correlating response rate and disease-free survival to metabolic features in the baseline spectrum and to changes in the spectrum occurring early following initiation of treatment. This application is the central one of 8 interactive R01 applications from institutions cooperating to study over 1500 patients with non-Hodgkin's lymphomas, locally-advanced breast cancers,sarcomas, and carcinomas of the head and neck. Attention will be paid to patient selection, protocol management, technical quality control and statistical analyses. The state-of-the-art techniques used will be uniform across the 8 institutions and will include: (1) The use of dual-tuned proton/phosphorus surface coils to interrogate various tumor anatomical locations. (2) Proton-decoupling of phosphorus spectra to distinguish individual components of phospholipid metabolites in the PME and PDE regions. (3) Image-guided 3-dimensional chemical shift imaging to accurately localize 13P NMR spectra to tumor masses, and (4) Molar quantitation of metabolite concentrations in the tumors. This application also proposes to establish standards for cooperative MRS trials in other diseases and clinical settings, and seeks to pave the way for clinical trials in which MRS could be used to intervene in the selection of treatment regimens in individual patients with cancer.